Gene therapy for XXXX using an adenovirus vector encoding soluble @entity6758 @entity7 receptor.

@entity1 @entity788 @entity7 @entity5 @entity19 @entity2279 @entity915 @entity6758
INTRODUCTION: @entity7 ( @entity7 ) plays an important role in @entity5 angiogenesis. The soluble form of @entity6758 @entity7 receptor inhibits @entity7 activity in a dominant-negative manner. AIM: This study demonstrated the regional @entity5 suppression effect of adenovirus-mediated soluble @entity6758 in @entity1 @entity788 cells. METHODOLOGY: The @entity7 expression level was examined in nine cell lines. Panc-1 and PK-8 were used as lower- and higher- @entity7 -producing cell lines, respectively. The in vitro proliferation of @entity5 cells infected with adenovirus vectors encoding soluble @entity6758 (Adsflt) and control vectors (AdLacZ) was not different. To assess the in vivo @entity5 growth suppression, @entity5 cells were inoculated subcutaneously in @entity915 @entity19 . Adsflt, AdLacZ, or vehicle was injected directly into the @entity5 . The early process of @entity5 angiogenesis in a dorsal skinfold chamber was monitored by intravital microscopy. RESULTS: In both Panc-1 cells and PK-8 cells, the @entity5 growth of the Adsflt-treated group was significantly suppressed. The microvessel density, revealed by @entity2279 immunostaining, was also significantly lower in the Adsflt-treated group. Apoptosis index was higher in the Adsflt group. Immunofluorescence staining revealed the expression of @entity7 not only in @entity5 cells but also in @entity5 stromal cells. Wild-type cells and AdLacZ-infected cells prompted strong @entity5 angiogenesis, whereas Adsflt-infected cells failed to exert such an effect. CONCLUSION: These results indicate that antiangiogenic gene therapy using soluble @entity6758 might be an effective approach for @entity788 treatment.
